EU/3/10/782

About

On 20 September 2010, orphan designation (EU/3/10/782) was granted by the European Commission to Mucokinetica Ltd, United Kingdom, for nafamostat mesilate for the treatment of cystic fibrosis.

Key facts

Active substance
Nafamostat mesilate
Disease / condition
Treatment of cystic fibrosis
Date of first decision
20/09/2010
Outcome
Positive
EU designation number
EU/3/10/782

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Mucokinetica Ltd
53 Cavendish Road
London SW12 0BL
United Kingdom
Telephone: +44 7774 12 1180
Telefax: +44 20 8673 2266
enquiries@mucokinetica.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating